Leonard Gunderson, MD, of the Mayo Clinic College of Medicine, discusses PET/CT imaging in upper and lower gastrointestinal cancers, which can be of value as a baseline study prior to treatment, in determining the degree of response to treatment, and in helping decide whether there is a relapse after a complete response to treatment.
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses this phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).
Reshma Jagsi, MD, DPhil, of the University of Michigan Health System, discusses this multicenter phase 1 study of veliparib given concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer (Abstract 312).
Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).
Anita Mahajan, MD, of MD Anderson Cancer Center, summarizes results from three clinical trials on radiation therapy for ependymoma, locally advanced thoracic esophageal squamous cell carcinoma, and meningioma (Abstracts 31, 1, 7).
Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline resectable and unresectable pancreatic tumors (Abstracts 253, 255, 351, 357).
